President DeGoia speaking of the importance of Geogetown Lombardi's NCI designationWhat makes Georgetown Lombardi Comprehensive Cancer Center different from other cancer centers? Georgetown University President John J. DeGioia shares his thoughts on the important work at Washington’s only National Cancer Institute-designated Comprehensive Cancer Center.

Watch President DeGioia's discussion

OncLive Strategic Alliance BadgeOncLive

OncLive and Georgetown Lombardi collaborate through OncLive's Strategic Alliance Partnership initiative

OncLive's Strategic Alliance

Lombardi News Stories

  • A man in a white coat is speaking
    Research in a Minute: Giuseppe Giaccone, MD, PhD

    As associate director of clinical research at Georgetown Lombardi Comprehensive Cancer Center and professor of medical oncology and pharmacology at Georgetown University School of Medicine, Giuseppe Giaccone, MD, PhD, leads a team of researchers in studying thymic carcinoma, also known as cancer of the thymus.

  • A brick sign for Frederick National Laboratory sits in a landscaped area outdoors
    Frederick National Laboratory and Georgetown Launch Research and Education Collaboration

    A new collaboration between Georgetown University and the Frederick National Laboratory for Cancer Research in Frederick, Maryland, aims to expand both institutions’ research and training missions in the biomedical sciences.

  • Image of the Georgetown University Medical and Dental building taken in the evening
    Family History Increases Breast Cancer Risk Even in Older Women: Weighing Screening Options

    Family history of breast cancer continues to significantly increase chances of developing invasive breast tumors in women ages 65 and older, according to research published by a team led by Dejana Braithwaite, PhD, associate professor of oncology at Georgetown University School of Medicine and a member of Georgetown Lombardi Comprehensive Cancer Center.

  • The Med-Dent building bathed in the fading light of day
    New Immunotherapy Combination Tolerable, Effective in Patients with Advanced Kidney Cancer

    A study led by Michael B. Atkins, MD, deputy director, Georgetown Lombardi Comprehensive Cancer Center, that combined an agent that blocks blood vessel formation with an immunotherapy agent was found to have promising anti-tumor activity and no unexpected side effects in an early-phase clinical trial in patients with advanced kidney cancer who had not been previously treated.